Aclaris Therapeutics, Inc. (LON:0H8T)

Aclaris Therapeutics Statistics

Total Valuation

LON:0H8T has a market cap or net worth of GBP 267.24 million. The enterprise value is 146.14 million.

Market Cap	267.24M
Enterprise Value	146.14M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	108.35M
Shares Outstanding	n/a
Shares Change (YoY)	+62.68%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	2.95%
Owned by Institutions (%)	58.78%
Float	82.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.82
PB Ratio	2.99
P/TBV Ratio	2.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.39
EV / Sales	12.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.57

Financial Position

The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.02.

Current Ratio	3.92
Quick Ratio	3.92
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -113.23% and return on invested capital (ROIC) is -32.23%.

Return on Equity (ROE)	-113.23%
Return on Assets (ROA)	-22.98%
Return on Invested Capital (ROIC)	-32.23%
Return on Capital Employed (ROCE)	-43.90%
Weighted Average Cost of Capital (WACC)	6.57%
Revenue Per Employee	185,891
Profits Per Employee	-1.67M
Employee Count	64
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +43.61% in the last 52 weeks. The beta is 0.43, so LON:0H8T's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	+43.61%
50-Day Moving Average	3.22
200-Day Moving Average	2.13
Relative Strength Index (RSI)	48.74
Average Volume (20 Days)	26,808

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.75

Income Statement

In the last 12 months, LON:0H8T had revenue of GBP 11.71 million and -105.40 million in losses. Loss per share was -0.91.

Revenue	11.71M
Gross Profit	-32.29M
Operating Income	-48.96M
Pretax Income	-105.40M
Net Income	-105.40M
EBITDA	-48.91M
EBIT	-48.96M
Loss Per Share	-0.91

Balance Sheet

The company has 71.35 million in cash and 1.67 million in debt, with a net cash position of 122.72 million.

Cash & Cash Equivalents	71.35M
Total Debt	1.67M
Net Cash	122.72M
Net Cash Per Share	n/a
Equity (Book Value)	89.35M
Book Value Per Share	0.82
Working Capital	55.77M

Cash Flow

In the last 12 months, operating cash flow was -31.93 million and capital expenditures -64,723, giving a free cash flow of -31.99 million.

Operating Cash Flow	-31.93M
Capital Expenditures	-64,723
Free Cash Flow	-31.99M
FCF Per Share	n/a

Margins

Gross Margin	-275.68%
Operating Margin	-418.06%
Pretax Margin	-900.01%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0H8T does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.68%
Shareholder Yield	-62.68%
Earnings Yield	-39.44%
FCF Yield	-11.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0H8T has an Altman Z-Score of -6.04 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.04
Piotroski F-Score	1